摘要
肾脏是系统性红斑狼疮最常累及的器官,即狼疮性肾炎。最近几十年,伴随生物医药研发、循证依据增加与临床指南更新,狼疮性肾炎诱导治疗已经发生了重大变迁,文章结合临床研究、指南更新及临床经验,介绍狼疮性肾炎诱导治疗方案的的演绎与变迁,旨在帮助临床医生了解狼疮性肾炎诱导治疗的最新策略和未来方向,以期提高狼疮性肾炎诱导治疗缓解率,改善患者预后。
Kidney is the most common organ involved in systemic lupus erythematosus (SLE), leading to inflamation of the kidney, i.e., lupus nephritis (LN). In recent decades, with the development of pharmaceutical research, increase of evidence and update of clinical guidelines, the induction therapy of LN has changed greatly. In combination with the clinical research, update of the guidelines and clinical experiences, we introduces the deduction and changes of the induction therapy of LN in this paper, and designed to help clinicians understand the latest strategies and future directions about the induction therapy of LN, so as to increase the remssion rate of LN after the induction therapy and improve the prognosis of LN patient.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2015年第6期471-474,共4页
Chinese Journal of Practical Internal Medicine
基金
"十二五"国家支撑计划课题(2011BAI10B04)
关键词
狼疮性肾炎
环磷酰胺
霉酚酸酯
钙调酶抑制剂
lupus nephritis
cyclophosphamide
mycophenolate
calcineurin inhibitors